Physician profile
Bailey E Tayebi
NPI 1528359668
$2,608.60
in general payments reported to CMS, 2019-2025
21 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $193 · 2021: $291 · 2022: $271 · 2023: $355 · 2024: $391 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864 · Long Term Medical Supply Or Device Loan: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.23 |
| Long Term Medical Supply Or Device Loan | $680.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,151.69 | 2019-2025 | |
| Integra Lifesciences Corporation | $694.79 | 2024-2025 | Amnioexcel, Cytal, Micromatrix |
| Organogenesis INC. | $121.96 | 2021-2023 | Puraply |
| Janssen Biotech, INC. | $98.76 | 2021-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $75.93 | 2024-2025 | |
| Pfizer INC. | $54.91 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.41 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $47.86 | 2020-2024 | Taltz, Olumiant |
| Amgen INC. | $45.25 | 2021-2024 | Otezla |
| Ucb, INC. | $39.51 | 2023-2024 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $35.37 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $33.88 | 2019-2025 | Nemluvio |
| Allergan, INC. | $28.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.26 | 2023 | Spevigo |
| Leo Pharma INC. | $19.45 | 2025 | Adbry |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.38 | 2025 | Dupixent |
| Abbvie INC. | $16.75 | 2019 | |
| Astellas Pharma US INC | $15.10 | 2020 | |
| Celgene Corporation | $14.99 | 2024 | Sotyktu |
| Incyte Corporation | $14.06 | 2024 | Opzelura |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Tayebi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.